Zhongshan Baiji Changsheng Pharmaceutical

Zhongshan Baiji Changsheng Pharmaceutical is a Chinese pharmaceutical company based in Zhongshan, Guangdong Province, primarily serving as a regional commercial and distribution entity for BeiGene. The company focuses on the sales, marketing, and supply chain management of innovative oncology and hematology treatments, including blockbuster therapies like zanubrutinib and tislelizumab. It plays a critical role in expanding the market reach of advanced biologics and small molecule inhibitors within the Southern China region. By leveraging its parent company's extensive R&D pipeline, Zhongshan Baiji Changsheng ensures the delivery of high-quality cancer therapeutics to hospitals and patients.